Safe, Clinician-Led Support for Sustainable Weight Management
Managing weight can be challenging, and medication is often an effective tool when combined with lifestyle guidance and medical supervision. At The Lab Clinic, we provide evidence-based consultations for weight management using prescription medicines like Wegovy and Mounjaro.
These treatments are integrated into a personalised plan tailored to your health needs and goals.
?
What Are Wegovy and Mounjaro?
Wegovy (semaglutide) and Mounjaro (tirzepatide) are prescription medicines approved for use as part of a medically supervised weight management plan. They belong to a class of medications that help regulate appetite and improve metabolic function, which can support weight loss in people who meet the clinical criteria.
These medications are not simple supplements — they are clinically proven therapies that require specialist assessment and ongoing monitoring.
Wegovy
Mounjaro
Weight management system
About Wegovy and Mounjaro
What is Wegovy®?
Wegovy® contains semaglutide, a GLP-1 receptor agonist.
It mimics your body’s natural GLP-1 hormone, which helps regulate appetite and blood sugar levels.
It works by:
-
Reducing hunger signals
-
Slowing gastric emptying
-
Helping you feel full for longer
Wegovy® is clinically indicated for chronic weight management when used alongside a reduced-calorie diet and increased physical activity.
In clinical studies, patients may experience average weight loss of approximately 5% to 15%, depending on individual response and adherence to lifestyle changes.
What is Mounjaro®?
Mounjaro® contains tirzepatide and acts on both GLP-1 and GIP receptors. This dual-action mechanism may enhance appetite regulation and improve metabolic control.
It works by:
-
Suppressing appetite
-
Improving insulin sensitivity
-
Supporting metabolic function
Clinical trials have shown significant weight reduction in eligible patients when combined with diet and exercise under medical supervision.
Am I Eligible?
Important Information
These medications are prescription-only treatments and are not suitable for everyone.
They are indicated for adults with:
• A Body Mass Index (BMI) ≥ 30 kg/m² (obesity), or
• A BMI ≥ 27 kg/m² and < 30 kg/m² (overweight) with at least one weight-related comorbidity such as:
-
Hypertension
-
Type 2 diabetes
-
Dyslipidaemia
-
Obstructive sleep apnoea
A full medical consultation is required to assess suitability. Individual factors including medical history, current medications, and overall health will be reviewed before any prescription is considered.
Important Information
Wegovy® and Mounjaro® are intended as part of a comprehensive weight management programme that includes lifestyle modification.
They are not cosmetic weight loss injections and should only be used under qualified medical supervision.
Are Weight Loss Medication Suitable for Everyone?
Weight management medications such as Wegovy® and Mounjaro® are not suitable for everyone.
A comprehensive medical assessment is required before prescribing. These medications may not be appropriate for individuals with certain medical conditions, specific medication use, or relevant personal or family history.
Weight management is not one-size-fits-all. Treatment plans must be tailored to each individual’s health profile and long-term goals.
What Are the Possible Side Effects of Wegovy® and Mounjaro®?
As with all prescription medicines, there are potential side effects.
Common side effects may include:
-
Nausea
-
Vomiting
-
Diarrhoea or constipation
-
Abdominal discomfort
-
Headache
-
Fatigue
-
Dizziness
Most side effects are gastrointestinal in nature and tend to improve over time as the body adjusts.
Dose escalation is typically gradual to help minimise these effects.
However, more serious side effects are possible and will be discussed during your consultation.
Ongoing medical supervision and follow-up are essential to ensure safety and tolerability.
Consultation Process
What to Expect at Your Consultation
During your initial visit, we will:
-
Review your medical and medication history.
-
Evaluate your weight management goals.
-
Discuss the potential benefits and risks of medications.
-
Recommend appropriate clinical pathways, including lifestyle support.
-
If appropriate, create an ongoing monitoring plan.
Medications like Wegovy and Mounjaro are prescription medicines and require regular review to ensure safety and effectiveness.
Consultation Fee
Frequently asked questions
Wegovy® (semaglutide) is an unfunded prescription medicine. Medicine costs and consultation fees apply.
Wegovy® FlexTouch® solution for injection is administered subcutaneously once weekly. Wegovy is indicated, as an adjunct to a reduced calorie diet and increased physical activity, for chronic weight management (weight loss and weight maintenance) in adults with an initial BMI ≥30 kg/m², or BMI ≥27 kg/m² to <30 kg/m² with at least one weight related comorbidity; and for weight management in adolescents aged 12 years and above with obesity and body weight >60 kg (specific continuation criteria apply). Wegovy is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease, BMI ≥27 kg/m², and without established type 1 or type 2 diabetes.
Common side effects may include nausea, vomiting, diarrhoea, constipation, abdominal pain, headache, and fatigue. Wegovy may not be suitable for everyone and requires a medical assessment. Please refer to the New Zealand Consumer Medicine Information and Medsafe data sheet for full prescribing information, warnings, precautions, and contraindications.
Mounjaro® (tirzepatide) is an unfunded prescription medicine. Medicine costs and consultation fees apply.
Mounjaro is administered subcutaneously once weekly. It is indicated for adults with insufficiently controlled type 2 diabetes mellitus (as an adjunct to diet and exercise, either alone when metformin is not tolerated or contraindicated, or in addition to other medicines), and for chronic weight management (weight loss and weight maintenance) in adults with an initial BMI ≥30 kg/m², or BMI ≥27 kg/m² to <30 kg/m² with at least one weight related comorbid condition.
Common side effects may include gastrointestinal symptoms such as nausea, vomiting, diarrhoea or constipation, and may also include headache and fatigue. Mounjaro may not be suitable for everyone and requires a medical assessment. Please refer to the New Zealand Consumer Medicine Information and Medsafe data sheet for full prescribing information, warnings, precautions, and contraindications.